RxDoctor Payments Data

Rony Kako, MD

Internal Medicine · Napa, CANPI 1699709881

Payments from drug & device makers

$928in general payments, 2019–2025

Across 49 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$119
  • Astellas Pharma US Inc$96
  • Novo Nordisk$95
  • Amgen$89
  • E.r. Squibb & Sons, L.L.C.$68
  • Boehringer Ingelheim$65
  • plus $396 from 15 others

What the payments were for

  • Food & beverage$91198%
  • Education$172%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$928 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$245,626
Medicare patients
328
Services billed
7,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban161$121,379
MyrbetriqMirabegron44$35,254
OzempicSemaglutide26$32,398
FarxigaDapagliflozin Propanediol47$22,240
JanuviaSitagliptin Phosphate13$20,893
XareltoRivaroxaban29$17,300
CreonLipase/Protease/Amylase15$17,219
JardianceEmpagliflozin25$14,773
PremarinEstrogens, Conjugated20$9,330
Potassium Chloride107$6,177
LinzessLinaclotide12$6,080
Nebivolol Hcl41$4,001
Atorvastatin Calcium273$3,935
PaxlovidNirmatrelvir/Ritonavir35$2,859
Rosuvastatin Calcium135$2,680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin, Paxlovid$46$133,568216 claims
Astellas Pharma US IncMyrbetriq$96$35,25444 claims
Novo NordiskOzempic$95$32,39826 claims
AbbVieCreon, Linzess$119$23,29827 claims
AstraZenecaFarxiga$19$22,24047 claims
Boehringer IngelheimJardiance$65$14,77325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Napa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →